ReviewTherapeutic advances in medical oncology2022
Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications.
Review in Therapeutic advances in medical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Lifecourse genome-wide association study meta-analysis refines the critical life stages for adiposity's influence on breast cancer risk.Science advances · 2026Pooled it
- Oestrogen changes at menopause: insights into obesity-associated breast risk and outcomes.Nature reviews. Endocrinology · 2026Review
- A Novel 10-Protein Score for Liver Fat Content Predicts Cardiovascular-Kidney-Metabolic Disease Risk.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- Research Progress of HER2 in Cervical Carcinoma.Cancer management and research · 2026Review
- Observational
- Article
- Is Body Mass Index a Prognostic Factor in Metastatic HER2-Positive Breast Cancer? A Real-World Multicenter Study.Medicina (Kaunas, Lithuania) · 2025Article
- Pre-treatment [18F]FDG PET/CT biomarkers for the prediction of antibody-drug conjugates efficacy in metastatic breast cancer.European journal of nuclear medicine and molecular imaging · 2025Article
- Predicting HER2 Status Associated with Breast Cancer Aggressiveness Using Four Machine Learning Models.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Impact of body mass index in therapeutic response for HER2 positive breast cancer treated with neoadjuvant targeted therapy: a multi-center study and meta-analysis.NPJ breast cancer · 2023Article
- The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis.Therapeutic advances in medical oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human Epidermal growth factor Receptor 2 (HER2) overexpression or
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.